Business · 27/02/2026Updated: 10/16/2026 · 1 min read
FDA Awards Priority Review Voucher to Sentynl Therapeutics for Rare Pediatric Disease Product ZYCUBO
Summary
The FDA has issued a priority review voucher to Sentynl Therapeutics for its rare pediatric disease product ZYCUBO, which was approved on January 12, 2026.
Original source language: Federal Register — Food and Drug AdministrationOpen original release →